Press release
Orally Disintegrating Tablet Market Poised for Robust Growth, Projected to Hit US$ 48.19 Billion by 2032 | Insights by Persistence Market Research
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/14572
The ODT market's accelerated expansion can be attributed to its growing adoption as an alternative to conventional tablets, particularly among elderly patients, children, and individuals with dysphagia. Unlike traditional tablets that require water, ODTs conveniently dissolve in the mouth, facilitating faster onset of action and improving patient compliance. Among various therapeutic areas, the Central Nervous System (CNS) segment has emerged as the leading segment, owing to the high prevalence of neurological conditions that demand rapid symptom relief. Geographically, North America is the dominant force, anticipated to hold a 39.2% share in 2025, supported by the region's advanced healthcare infrastructure, strong pharmaceutical presence, and high healthcare expenditure.
Key Highlights from the Report
✦ North America is projected to hold a 39.2% share in 2025 due to its robust healthcare infrastructure and pharmaceutical presence.
✦ The Anti-Psychotic Drugs segment is estimated to contribute 19.7% market share in 2025, led by the need for enhanced patient compliance.
✦ CNS disorders account for the largest disease indication segment, driven by rising neurological cases and the need for rapid medication onset.
✦ Innovations in taste-masking and bioavailability techniques are strengthening global ODT adoption and enhancing patient satisfaction.
✦ Growing investment in R&D and emerging markets in Asia-Pacific are unlocking new opportunities for ODT manufacturers.
✦ Rising elderly population and pediatric usage are driving the global demand for easy-to-administer tablet formulations.
Market Segmentation
The orally disintegrating tablet market is segmented based on drug class, disease indication, and end-user. In terms of drug class, anti-psychotic drugs are expected to dominate the market with a 19.7% share by 2025, owing to the wide use of these formulations in managing psychiatric conditions such as schizophrenia, bipolar disorder, and major depression. The need for rapid onset and ease of administration in such cases enhances ODT preference.
When analyzing by disease indication, the Central Nervous System (CNS) disorders segment stands as the leader, anticipated to capture a 56.7% market share in 2025. The high prevalence of neurological disorders, such as epilepsy, Parkinson's disease, and migraine, contributes to this growth. The convenience of ODTs for patients experiencing dysphagia or nausea further supports the segment's expansion.
From the end-user perspective, the hospital pharmacies segment remains a key distribution channel, given the rising number of prescriptions for ODT formulations intended for both inpatient and outpatient settings. The easy administration of ODTs during emergency care and routine treatment contributes to their prominence in healthcare institutions.
Regional Insights
North America is expected to lead the global ODT market through the forecast period, with an estimated market share of 39.2% in 2025. The region's dominance is underpinned by advanced healthcare systems, a high rate of chronic disease diagnoses, and the strong presence of pharmaceutical manufacturers prioritizing ODT formulations.
Europe follows as the second-largest and fastest-growing region, projected to hold a 29.1% market share in 2025. The region benefits from favorable reimbursement policies and regulatory support for innovative drug delivery systems. Additionally, Europe's aging population significantly contributes to the increased adoption of ODTs.
Meanwhile, South Asia & Oceania represent emerging hotspots for the ODT market. Countries like India are witnessing increased demand for ODTs, supported by an expanding geriatric population, rising healthcare awareness, and growing pharmaceutical manufacturing capabilities. These factors are positioning the region as a key growth contributor in the years ahead.
Market Drivers
The ODT market is propelled by several significant factors. Primarily, the growing preference for easy-to-administer dosage forms is creating a steady demand for ODTs, particularly among pediatric and geriatric populations. The tablets' ability to dissolve without water is a game changer for patients who face swallowing difficulties. Additionally, the rising prevalence of CNS disorders and psychiatric conditions, which require rapid therapeutic action, boosts ODT adoption. Pharmaceutical manufacturers are investing in taste-masking technologies and enhanced drug delivery mechanisms, which are not only improving the efficacy and palatability of these tablets but also driving patient adherence.
Market Restraints
Despite the strong growth potential, the market faces challenges. One key restraint is the limited drug load capacity inherent in ODT formulations, which restricts their use to medications requiring lower doses. This limitation narrows the range of diseases that can be effectively treated using ODTs, thus limiting market potential for certain drug classes. Moreover, the requirement for specialized packaging to protect ODTs from moisture and breakage during storage and transportation increases manufacturing costs and logistical complexities.
Market Opportunities
The ODT market presents significant opportunities, particularly in emerging economies, where healthcare access is rapidly improving. Pharmaceutical companies have the potential to expand their footprint by developing ODT versions of high-demand medications for chronic and neurological conditions. Technological innovations, such as nanotechnology for improved bioavailability and advanced taste-masking systems, further open the door for a new wave of product launches. Partnerships between biotech firms and established pharmaceutical giants can also drive expansion into new therapeutic areas.
Frequently Asked Questions (FAQs)
How Big is the Orally Disintegrating Tablet Market?
Who are the Key Players in the Global Orally Disintegrating Tablet Market?
What is the Projected Growth Rate of the Orally Disintegrating Tablet Market?
What is the Market Forecast for Orally Disintegrating Tablets for 2032?
Which Region is Estimated to Dominate the Orally Disintegrating Tablet Industry through the Forecast Period?
Company Insights
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Mylan N.V.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited
• Catalent, Inc.
• Dr. Reddy's Laboratories Ltd.
Recent Developments:
In July 2024, Mind Medicine (MindMed) Inc. announced that the USPTO granted a new patent for MM120, a promising candidate for treating mental health disorders in ODT form.
In March 2023, Zydus Lifesciences secured final approval from the USFDA to market Olanzapine Orally Disintegrating Tablets USP, further strengthening its CNS portfolio.
Conclusion
The global orally disintegrating tablet market is evolving rapidly, supported by innovations in formulation technologies and the rising demand for patient-friendly drug delivery systems. With its strong foothold in neurological and psychiatric treatments and growing acceptance across emerging healthcare markets, the ODT sector promises sustained growth in the years ahead. As pharmaceutical companies continue to address challenges like drug load limitations and taste-masking, ODTs are expected to play an increasingly central role in global healthcare. The market's expansion to nearly US$ 48,186.8 million by 2032 reflects its strategic importance in modern pharmaceutical therapy.
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com
About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orally Disintegrating Tablet Market Poised for Robust Growth, Projected to Hit US$ 48.19 Billion by 2032 | Insights by Persistence Market Research here
News-ID: 3977149 • Views: …
More Releases from Persistence Market Research
Global Automotive Active Health Monitoring Systems Market Expected to Surge from …
The Automotive Active Health Monitoring Systems Market is poised for significant growth over the forecast period of 2025 to 2032. This market is projected to expand from USD 683.9 million in 2025 to USD 2,338.3 million by 2032, registering a robust CAGR of 19.20%. Automotive active health monitoring systems are designed to track the real-time status of vehicles, enabling predictive maintenance, reducing downtime, and enhancing overall vehicle safety. With growing…
Primary Packaging Labels Market to Reach US$12.2 Bn by 2031 with Steady Growth a …
➤Overview of the Market
The global primary packaging labels market is a crucial segment of the packaging industry, enabling product identification, regulatory compliance, and brand differentiation. Primary labels are applied directly on product packaging, such as bottles, vials, boxes, and pouches, serving both functional and promotional roles. As consumer awareness of product authenticity and safety continues to rise, demand for innovative labeling solutions is expanding. Moreover, stringent regulatory frameworks in industries…
Shelf Stable Packaging Market to Reach US$10.7 Bn by 2031 with Steady Growth at …
➤Overview of the Market
The shelf stable packaging market plays a critical role in extending the shelf life of food and beverages without the need for refrigeration, ensuring product safety, convenience, and affordability. These packaging solutions-spanning cartons, pouches, cans, and plastic containers-are widely used in ready-to-eat meals, dairy alternatives, sauces, soups, and beverages. Growth in the market is closely linked to evolving consumer lifestyles, increasing urbanization, and demand for long-lasting packaged…
Print Label Market to Reach US$68.6 Bn by 2031 with Steady Growth at 4.3% CAGR - …
➤Overview of the Market
The global print label market is poised for substantial expansion, driven by increasing demand across industries such as food & beverages, pharmaceuticals, cosmetics, and logistics. Labels play a crucial role in brand identity, product differentiation, and regulatory compliance. In addition to providing essential information like product ingredients, expiration dates, and barcodes, printed labels serve as key marketing tools that influence consumer purchase decisions. With the rapid rise…
More Releases for ODT
Phase 3 Clinical Trial for Major Depressive Disorder Treatment Market Begins 202 …
The Global Major Depressive Disorder Market size reached US$ 6.84 billion in 2024 and is expected to reach US$ 14.57 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.
The Major Depressive Disorder Market report, released by DataM Intelligence, offers comprehensive insights and thorough analysis of major market trends, growth prospects, and emerging challenges. With a strong focus on actionable intelligence, DataM Intelligence equips businesses with…
Orally Disintegrating Tablet (ODT) Market Analysis, Size, Current Scenario and F …
Orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period. According to the US Food and Drug Administration (FDA), ODT's are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the forecast period is…
Orally Disintegrating Tablet (ODT) Market Share 2021 Growth Challenges, Opportun …
The global orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). According to the US Food and Drug Administration (FDA), ODT’s are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the…
Orally Dissolving Tablets (ODT) Excipient Market global outlook and forecast 202 …
The Global Orally Dissolving Tablets (ODT) Excipient Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Orally Dissolving Tablets (ODT) Excipient makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and…
Investigation announced for Long-Term Investors in shares of Odonate Therapeutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Odonate Therapeutics, Inc..
Investors who are current long term investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ODT stocks follows a lawsuit filed against Odonate…
Deadline on Nov. 16th coming up in Lawsuit for Investors in Odonate Therapeutics …
The Shareholders Foundation announced that a deadline is coming up on November 16, 2020 in the lawsuit filed for certain investors of Odonate Therapeutics, Inc. (NASDAQ: ODT) over alleged securities laws violations by Odonate Therapeutics, Inc.
Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and there are strict and short deadlines running. Deadline: November 16, 2020. NASDAQ: ODT stockholders should contact the Shareholders Foundation at…
